Glial cell reprogramming

Glial cell reprogramming, also known as in situ neuronal reprogramming or glial-to-neuron conversion, is a therapeutic strategy aimed at regenerating lost neurons by converting endogenous non-neuronal cells directly into functional neurons [1, 2]. This approach typically targets glial populations, such as astrocytes, NG2 glia, or Müller glia, which are naturally abundant and often proliferate in response to injury or neurodegeneration [4, 5]. The conversion process is driven by the ectopic expression of key transcription factors—including NeuroD1, Ascl1, and Sox2—or by the use of chemical cocktails that modulate epigenetic states and signaling pathways like Notch and TGF-beta [3, 11]. Unlike traditional stem cell transplantation, this method utilizes the brain's own cellular resources, potentially avoiding immune rejection and eliminating the need for complex surgical procedures [5, 10]. It is being actively investigated for conditions such as Parkinson’s disease, Alzheimer’s disease, stroke, and spinal cord injury [5, 9]. However, significant challenges remain, including ensuring full neuronal maturation, achieving precise synaptic integration, and managing the potential loss of vital support functions provided by the original glial population [1, 4, 10].

Other names

Glial-to-neuron conversionIn situ neuronal reprogrammingDirect lineage reprogramming of gliaNeuroglial cell reprogrammingGlia transdifferentiation

Involves the ectopic expression of neurogenic transcription factors (e.g., NeuroD1, Ascl1) or the application of small molecule cocktails to modulate signaling pathways such as Notch inhibition, HDAC inhibition, and TGF-beta signaling, thereby converting endogenous glial cells into functional neurons.